🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to researchers.

A Global Challenge

The sexually transmitted infection are escalating around the world, with figures suggesting over 82 million new cases per year. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the context of growing infection rates, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This approval marks a huge turning point in the therapy of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

Based on findings detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which involves two antibiotics. The study included nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Clinicians treating patients have shared positive views. Having a easy-to-administer therapy such as this is seen as a "revolutionary step" for public health efforts. This is deemed vital to reduce the burden of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.